|Articles|November 16, 2020
- Pharmaceutical Executive-11-01-2020
- Volume 40
- Issue 11
Pharmaceutical Executive, November 2020 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive November 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 5 years ago
Synthetic Biology and the Environmentover 5 years ago
Measuring Pharma’s Wider Mandateover 5 years ago
Patients as the North Starover 5 years ago
A Rare-Disease Must? Building Long-Term Relationshipsover 5 years ago
Making Remote Work a Success Beyond COVIDover 5 years ago
CRISPR for Diversity, and Humanity’s, Sakeover 5 years ago
Expediting the Cancer Treatment Pathover 5 years ago
Vaccine Authorization, Distribution Raise Multiple Challengesover 5 years ago
EU Leaders in High-Stakes Gamble on COVID ResponsesAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report
5